Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (ATRA)
A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)
Sponsor: Mario Negri Institute for Pharmacological Research
Terminated
Low enrolment rate
Other terminated trials from Mario Negri Institute for Pharmacological Research
- Hyperkalemia · Phase PHASE3 · Nov 2024
- Fallopian Tube Cancer · Phase PHASE2 · Aug 2024
- Lung Cancer · Phase PHASE3 · Sep 2022
- Open Angle Glaucoma · Phase NA · Apr 2022
- Rheumatoid Arthritis · Phase PHASE4 · Dec 2021
See all terminations from Mario Negri Institute for Pharmacological Research
Other Breast Neoplasm Female trials with similar outcome
Listed as NCT04113863, this PHASE2 trial focuses on Breast Neoplasm Female and remains terminated or withdrawn. Sponsored by Mario Negri Institute for Pharmacological Research, it has been updated 9 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Dec 2025 — Jan 2026 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Dec 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Apr 2023 — Nov 2023 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Nov 2021 — Apr 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mario Negri Institute for Pharmacological Research
For direct contact, visit the study record on ClinicalTrials.gov .